Seegene Announces Q4 and Full-Year 2021 Financial Results
Total sales of 2021 stood at KRW 1.37 trillion, a 22% increase YoY Q4 Revenue of KRW 410 billion, up 34% QoQ Operating profit held steady YoY at KRW 666.7 billion despite its tripled strategic investments in R&D Seegene to make a strategic shift to a 'molecular...
Frost & Sullivan Reveals Strategic Growth Opportunities Amidst Global Economic Recovery in 2022
Think Tank will explore how sustainability, digitalization and economic trends across regions are shaping regional and industry outlook SAN ANTONIO, Feb. 17, 2022 /PRNewswire/ -- While the global economy is on the path to recovery, restraints continue to emanate from cost-of-living pressures and supply chain disruptions. The world economy is also at the cusp of transformation, driven by the clean...
Small Molecule Targeting CD47-SIRPα Pathway: Insilico Medicine Achieves its First Major Milestone in Fosun Pharma Collaboration with the Nomination of Preclinical Candidate for QPCTL
SHANGHAI and NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery and development company, today announced that it has used its proprietary AI platform to nominate a preclinical candidate compound (PCC) for innovative cancer immunotherapy for its QPCTL program. Notably, this is the first major milestone achieved by Insilico in the...
BioWorld by Clarivate Provides In-depth Analyses of Long COVID Studies, Potentially the Next Public Health Crisis
40-plus therapeutics in development even as researchers are trying to reach consensus on the syndrome LONDON, Feb. 17, 2022 /PRNewswire/ -- BioWorld published by Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, has announced new analysis tracking the latest developments related to the study of long...
Kato Wins FDA Approval for Human Studies of Drug for Retinal Disorders
Resolv ER™ may remedy leading causes of blindness in adults LAGUNA HILLS, Calif., Feb. 17, 2022 /PRNewswire/ -- Kato Pharmaceuticals, a privately-held clinical stage biopharmaceutical company, today announced that the FDA has approved the company's investigational new drug (IND) application to conduct human studies using Resolv ER™ for the treatment of Vitreomacular Attachment (VMA). This first-in-class patented formulation...
CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan,...
SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the Taiwan Food and Drug Administration (TFDA) has confirmed the acceptance of the new drug application (NDA) for pralsetinib for the treatment of rearranged during transfection (RET) fusion-positive...
Cambridge Nutranostics has developed a point-of-care OCCL test prototype for testing blood plasma oxygen to monitor pregnancy health
CAMBRIDGE, England, Feb. 17, 2022 /PRNewswire/ -- Cambridge Nutranostics Ltd (CNL, http://www.occltest.com) has begun to validate in clinic its first prototype of a test to assess and monitor plasma oxygen, the part of the total blood O2, which can cross the capillary wall and deliver this essential gas for tissue cell respiration. This test would require only one drop of...
Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the primary endpoint was met in two Chinese registration studies of recombinant full-human anti-PCSK-9 monoclonal antibody (R&D code: IBI306,...
BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein
SUGGESTS superior cardiAC safety compared to mRNA AND ADENOVIRUS VECTOR vaccines VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, demonstrate that the vaccine does not bind to the Angiotensin...
LIMACORPORATE’S ADVANCED TESTING FACILITY RECEIVES ISO 17025 CERTIFICATION BY ACCREDIA
UDINE, Italy, Feb. 16, 2022 /PRNewswire/ -- LimaCorporate is proud to announce the ISO 17025 accreditation by Accredia. This important achievement covers the activities of ATLAs, the company's Advanced Laboratory for Testing and Analysis. ATLAs is the core of the experimental verification and simulation of advanced and innovative materials, production processes...
